Dose and plasma concentration of galantamine in Alzheimer's disease - Clinical application

Alzheimer's Research and Therapy

Volumn 5, Issue 1, 2013, Pages

  Wattmo, Carina ^a,b   Jedenius, Erik ^c,d   Blennow, Kaj ^e   Wallin, Åsa K ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d Medical Department   (Sweden)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4; GALANTAMINE;

AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD SAMPLING; BODY MASS; BODY WEIGHT; COGNITION; DAILY LIFE ACTIVITY; DEMOGRAPHY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SWEDEN;

EID: 84871721290     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt156     Document Type: Article

References (23)

1. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy. DG Wilkinson, PT Francis, E Schwam, J Payne-Parrish, Drugs Aging 2004 21 453 478 10.2165/00002512-200421070-00004 15132713
2. Galantamine for Alzheimer's disease and mild cognitive impairment. C Loy, L Schneider, Cochrane Database Syst Rev 2006 CD001747
3. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease. H Brodaty, J Corey-Bloom, FC Potocnik, L Truyen, M Gold, CR Damaraju, Dement Geriatr Cogn Disord 2005 20 120 132 10.1159/000086613 15990426
4. Cholinesterase inhibitors for Alzheimer's disease. J Birks, Cochrane Database Syst Rev 2006 CD005593
5. Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. CW Ritchie, D Ames, T Clayton, R Lai, Am J Geriatr Psychiatry 2004 12 358 369 15249273
6. Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. DS Geldmacher, G Provenzano, T McRae, V Mastey, JR Ieni, J Am Geriatr Soc 2003 51 937 944 10.1046/j.1365-2389.2003.51306.x 12834513
7. Effect of gender and apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimer's disease. SH MacGowan, GK Wilcock, M Scott, Int J Geriatr Psychiatry 1998 13 625 630 10.1002/(SICI)1099-1166(199809) 13:9<625::AID-GPS835>3.0.CO;2-2 9777427
8. Predictors of long-term cognitive outcome in Alzheimer's disease. C Wattmo, AK Wallin, E Londos, L Minthon, Alzheimers Res Ther 2011 3 23 10.1186/alzrt85 21774798
9. Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galantamine. T Darreh-Shori, A Kadir, O Almkvist, M Grut, A Wall, G Blomquist, B Eriksson, B Langstrom, A Nordberg, Neurobiol Aging 2008 29 168 184 10.1016/j.neurobiolaging.2006.09.020 17196712
10. Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease. P Davidsson, K Blennow, N Andreasen, B Eriksson, L Minthon, C Hesse, Neurosci Lett 2001 300 157 160 10.1016/S0304-3940(01)01586-5 11226635
11. Diagnostic and statistical manual of mental disorders: DSM-IV. A Frances, American Psychiatric Association, Prepared by the Task Force on DSM-IV Washington, D.C.: American Psychiatric Association 4 1994
12. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. G McKhann, D Drachman, M Folstein, R Katzman, D Price, EM Stadlan, Neurology 1984 34 939 944 10.1212/WNL.34.7.939 6610841
13. «Mini-mental state». A practical method for grading the cognitive state of patients for the clinician. MF Folstein, SE Folstein, PR McHugh, J Psychiatr Res 1975 12 189 198 10.1016/0022-3956(75)90026-6 1202204
14. A new rating scale for Alzheimer's disease. WG Rosen, RC Mohs, KL Davis, Am J Psychiatry 1984 141 1356 1364 6496779
15. Assessment of older people: self-maintaining and instrumental activities of daily living. MP Lawton, EM Brody, Gerontologist 1969 9 179 186 10.1093/geront/9.3-Part-1.179 5349366
16. High-performance liquid chromatographic method with UV photodiode-array, fluorescence and mass spectrometric detection for simultaneous determination of galantamine and its phase I metabolites in biological samples. J Malakova, M Nobilis, Z Svoboda, M Lisa, M Holcapek, J Kvetina, J Klimes, V Palicka, J Chromatogr B Analyt Technol Biomed Life Sci 2007 853 265 274 10.1016/j.jchromb.2007.03.025 17416214
17. Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer's disease. L Parnetti, D Chiasserini, U Andreasson, M Ohlson, C Huls, H Zetterberg, L Minthon, AK Wallin, N Andreasen, VN Talesa, K Blennow, Acta Neurol Scand 2011 124 122 129 10.1111/j.1600-0404.2010.01435.x 20880294
18. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. T Darreh-Shori, O Almkvist, ZZ Guan, A Garlind, B Strandberg, AL Svensson, H Soreq, E Hellstrom-Lindahl, A Nordberg, Neurology 2002 59 563 572 10.1212/WNL.59.4.563 12196650
19. Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients. A Nordberg, T Darreh-Shori, E Peskind, H Soininen, M Mousavi, G Eagle, R Lane, Curr Alzheimer Res 2009 6 4 14 10.2174/ 156720509787313961 19199870
20. Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study. A Santoro, P Siviero, N Minicuci, E Bellavista, M Mishto, F Olivieri, F Marchegiani, AM Chiamenti, L Benussi, R Ghidoni, B Nacmias, S Bagnoli, A Ginestroni, O Scarpino, E Feraco, W Gianni, G Cruciani, R Paganelli, A Di Iorio, M Scognamiglio, LM Grimaldi, C Gabelli, S Sorbi, G Binetti, G Crepaldi, C Franceschi, CNS Drugs 2010 24 163 176 10.2165/11310960-000000000-00000 20088621
21. Long-term outcome and prediction models of activities of daily living in Alzheimer disease with cholinesterase inhibitor treatment. C Wattmo, AK Wallin, E Londos, L Minthon, Alzheimer Dis Assoc Disord 2011 25 63 72 10.1097/WAD.0b013e3181f5dd97 20847636
22. Changes in the activity and protein levels of CSF acetylcholinesterases in relation to cognitive function of patients with mild Alzheimer's disease following chronic donepezil treatment. T Darreh-Shori, L Meurling, T Pettersson, K Hugosson, E Hellstrom-Lindahl, N Andreasen, L Minthon, A Nordberg, J Neural Transm 2006 113 1791 1801 10.1007/s00702-006-0526-2 16868793
23. Galantamine population pharmacokinetics in patients with Alzheimer's disease: modeling and simulations. V Piotrovsky, A Van Peer, N Van Osselaer, M Armstrong, J Aerssens, J Clin Pharmacol 2003 43 514 523 12751272